Guggenheim analyst Debjit Chattopadhyay lowered the firm’s price target on BioMarin (BMRN) to $86 from $106 and keeps a Buy rating on the shares. The likely impact of a potential competitor launch to the Voxzogo franchise were a drag on the below-consensus guidance for FY26 Voxzogo sales, but headwinds to Voxzogo and discontinuation of Roctavian are counterbalanced by potential closing of the Amicus (FOLD) acquisition, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin price target lowered to $55 from $60 at H.C. Wainwright
- BioMarin Earnings Call Highlights Growth, Pipeline, Deals
- BioMarin price target lowered to $95 from $98 at Oppenheimer
- BioMarin price target lowered to $97 from $102 at BofA
- BioMarin: Strong Q4 Beat, Solid Multi‑Year Outlook, and Strategic Amicus Acquisition Support Buy Rating